Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$649M |
| 2 |
Nike
NKE
|
+$453M |
| 3 |
Tesla
TSLA
|
+$431M |
| 4 |
AstraZeneca
AZN
|
+$389M |
| 5 |
Coca-Cola
KO
|
+$336M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$897M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$578M |
| 3 |
Moderna
MRNA
|
+$438M |
| 4 |
Apple
AAPL
|
+$417M |
| 5 |
Aon
AON
|
+$386M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.55% |
| 2 | Technology | 20.49% |
| 3 | Consumer Staples | 11.15% |
| 4 | Consumer Discretionary | 9.9% |
| 5 | Industrials | 8.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NMRD
2876
DELISTED
Nemaura Medical, Inc. Common Stock
NMRD
| $520K | ﹤0.01% |
86,500
+57,674
| +200% | +$415K |
|
|
CLVS
2877
DELISTED
Clovis Oncology, Inc.
CLVS
| $520K | ﹤0.01% |
+116,700
| New | +$562K |
|
2878
iShares Global 100 ETF
IOO
$9.46B
| $519K | ﹤0.01% |
+7,300
| New | +$534K |
|
2879
Shinhan Financial Group
SHG
$35.6B
| $512K | ﹤0.01% |
+15,200
| New | +$508K |
|
2880
Afya
AFYA
$1.24B
| $511K | ﹤0.01% |
25,900
+8,600
| +50% | +$195K |
|
2881
Digi International
DGII
$3.23B
| $509K | ﹤0.01% |
24,200
-83,721
| -78% | -$1.73M |
|
|
SELF
2882
Global Self Storage
SELF
$59M
| $509K | ﹤0.01% |
98,900
+25,700
| +35% | +$134K |
|
2883
XPEL
XPEL
$1.4B
| $508K | ﹤0.01% |
6,700
-16,400
| -71% | -$1.35M |
|
|
FNCB
2884
DELISTED
FNCB Bancorp Inc. Common Stock
FNCB
| $508K | ﹤0.01% |
61,718
-31,882
| -34% | -$246K |
|
2885
Targa Resources
TRGP
$58.7B
| $507K | ﹤0.01% |
+10,300
| New | +$453K |
|
2886
Pliant Therapeutics
PLRX
$65.6M
| $506K | ﹤0.01% |
+30,000
| New | +$637K |
|
2887
Sonoma Pharmaceuticals
SNOA
$6.27M
| $506K | ﹤0.01% |
4,533
-75
| -2% | -$9.23K |
|
2888
John Wiley & Sons Class A
WLY
$2.65B
| $506K | ﹤0.01% |
+9,700
| New | +$556K |
|
2889
Simmons First National
SFNC
$3.46B
| $505K | ﹤0.01% |
+17,088
| New | +$483K |
|
2890
Business First Bancshares
BFST
$1.05B
| $503K | ﹤0.01% |
21,500
-600
| -3% | -$13.9K |
|
|
BSCL
2891
DELISTED
Invesco BulletShares 2021 Corporate Bond ETF
BSCL
| $503K | ﹤0.01% |
23,845
-204,749
| -90% | -$4.32M |
|
2892
Nuvation Bio
NUVB
$2.1B
| $501K | ﹤0.01% |
50,400
-416,400
| -89% | -$3.77M |
|
2893
National CineMedia
NCMI
$261M
| $500K | ﹤0.01% |
14,056
-22,550
| -62% | -$732K |
|
2894
loanDepot
LDI
$309M
| $498K | ﹤0.01% |
+73,581
| New | +$687K |
|
2895
ProShares Ultra Technology
ROM
$1.33B
| $497K | ﹤0.01% |
+10,000
| New | +$531K |
|
|
LONA
2896
LeonaBio Inc
LONA
$73.8M
| $495K | ﹤0.01% |
+5,273
| New | +$537K |
|
|
VINC
2897
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $495K | ﹤0.01% |
1,530
-1,925
| -56% | -$562K |
|
2898
Sabra Healthcare REIT
SBRA
$5.12B
| $494K | ﹤0.01% |
33,580
-877,099
| -96% | -$14.8M |
|
2899
Tempest Therapeutics
TPST
$16.5M
| $493K | ﹤0.01% |
2,623
+556
| +27% | +$108K |
|
2900
FTAI Aviation
FTAI
$22.3B
| $492K | ﹤0.01% |
+22,681
| New | +$543K |
|
Similar funds
Jim Simons's Q3 2021 Portfolio in Review
As of Q3 2021, Jim Simons held 4,070 positions worth $77.4B, down 3.3% from $80.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons's Q3 2021 filing shows 663 new, 931 increased, 1,797 reduced and 653 closed positions. Its largest new stake was Adobe: 1,030,433 shares worth $593M. The largest sale was Amazon, an estimated $897M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Technology and Consumer Staples.
- Jim Simons's largest Q3 2021 buy was Adobe: 1,030,433 shares worth $593M.
- Jim Simons added most to Nike in Q3 2021, an estimated $453M increase.
- Jim Simons's biggest Q3 2021 reduction was Moderna, cutting an estimated $438M.
- Jim Simons fully exited Amazon in Q3 2021, selling an estimated $897M.
- Jim Simons's ten largest holdings make up 12% of its $77.4B portfolio in Q3 2021.
- Jim Simons opened 663 new positions and closed 653 in Q3 2021.
- Jim Simons's portfolio value fell 3.3% quarter-over-quarter to $77.4B.
Based on Renaissance Technologies's 13F filing for Q3 2021, filed 12 Nov 2021.